Abeona Therapeutics (NASDAQ:ABEO) Earns Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Abeona Therapeutics (NASDAQ:ABEO - Free Report) in a report published on Monday,Benzinga reports. The firm currently has a $20.00 target price on the biopharmaceutical company's stock.

A number of other equities research analysts have also recently weighed in on ABEO. Stifel Nicolaus cut their price target on Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating on the stock in a report on Friday, May 16th. Wall Street Zen cut shares of Abeona Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 15th. Oppenheimer started coverage on shares of Abeona Therapeutics in a research report on Monday, June 2nd. They set an "outperform" rating and a $19.00 price objective on the stock. Finally, Alliance Global Partners reiterated a "buy" rating on shares of Abeona Therapeutics in a research report on Thursday, May 15th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, Abeona Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $19.25.

Abeona Therapeutics Stock Up 0.5%

Shares of Abeona Therapeutics stock traded up $0.03 during trading hours on Monday, hitting $5.95. 593,700 shares of the company's stock traded hands, compared to its average volume of 702,549. The stock has a 50 day simple moving average of $6.01 and a 200-day simple moving average of $5.58. The company has a quick ratio of 4.90, a current ratio of 4.90 and a debt-to-equity ratio of 0.27. The company has a market cap of $304.40 million, a PE ratio of -4.69 and a beta of 1.51. Abeona Therapeutics has a twelve month low of $3.93 and a twelve month high of $7.32.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.11. Equities research analysts anticipate that Abeona Therapeutics will post -1.16 earnings per share for the current fiscal year.

Insider Activity at Abeona Therapeutics

In related news, CEO Vishwas Seshadri sold 69,420 shares of Abeona Therapeutics stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $5.86, for a total value of $406,801.20. Following the completion of the sale, the chief executive officer owned 1,234,341 shares of the company's stock, valued at approximately $7,233,238.26. The trade was a 5.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Faith L. Charles sold 10,738 shares of Abeona Therapeutics stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $5.86, for a total transaction of $62,924.68. Following the completion of the sale, the director directly owned 139,094 shares of the company's stock, valued at approximately $815,090.84. The trade was a 7.17% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 238,124 shares of company stock worth $1,466,054. 5.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Abeona Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Goldman Sachs Group Inc. lifted its stake in shares of Abeona Therapeutics by 49.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 200,450 shares of the biopharmaceutical company's stock valued at $954,000 after purchasing an additional 66,422 shares during the last quarter. Newtyn Management LLC lifted its position in Abeona Therapeutics by 26.3% during the 1st quarter. Newtyn Management LLC now owns 480,000 shares of the biopharmaceutical company's stock worth $2,285,000 after acquiring an additional 100,000 shares during the last quarter. Trexquant Investment LP lifted its position in Abeona Therapeutics by 74.1% during the 1st quarter. Trexquant Investment LP now owns 119,274 shares of the biopharmaceutical company's stock worth $568,000 after acquiring an additional 50,758 shares during the last quarter. OMERS ADMINISTRATION Corp lifted its position in Abeona Therapeutics by 11.0% during the 1st quarter. OMERS ADMINISTRATION Corp now owns 72,200 shares of the biopharmaceutical company's stock worth $344,000 after acquiring an additional 7,155 shares during the last quarter. Finally, Wellington Management Group LLP lifted its position in Abeona Therapeutics by 64.1% during the 1st quarter. Wellington Management Group LLP now owns 153,121 shares of the biopharmaceutical company's stock worth $729,000 after acquiring an additional 59,832 shares during the last quarter. Institutional investors and hedge funds own 80.56% of the company's stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.